When gout treatment stalls, check the dose

By Nirbhay Agarwal · 19 August 2026 · 5 min read

There is a specific kind of stuck that gout patients end up in, and it is worth naming because it looks like something else.

You were prescribed allopurinol. You have taken it every day. You are two years in. You still get flares, and your uric acid — on the rare occasion it gets measured — is still sitting above 7.0 mg/dL. The obvious conclusion is that allopurinol does not work for you.

Usually the actual answer is duller than that. You are on the starting dose.

The instruction has two halves

The 2020 American College of Rheumatology guideline strongly recommends starting allopurinol at a low dose — under 100 mg a day, and lower again in kidney disease. That is deliberate, and it is good practice: a lower starting dose reduces the flare risk that comes with beginning treatment, which is the thing that makes gout look worse before it gets better.

But “start low” is only half a sentence. The full recommendation reads:

For allopurinol and febuxostat, we strongly recommend starting at a low dose with subsequent dose titration to target over starting at a higher dose.

And it sits alongside two others, both also graded strong:

For all patients taking ULT, we strongly recommend a treat-to-target strategy of ULT dose management that includes dose titration and subsequent dosing guided by serial SU values to achieve an SU target over a fixed, standard-dose ULT strategy.

For all patients taking ULT, we strongly recommend continuing ULT to achieve and maintain an SU target of <6.0 mg/dL over no target.

That second one is graded strong on high-certainty evidence — the top of both scales the guideline uses.

Read together, they describe a process, not a prescription. The dose is supposed to be a dial that gets turned until a number crosses a line, and then left where it lands. A dose that was correct on day one is not thereby correct on day four hundred. It was a starting point.

What being on the starting dose looks like

This is the state a lot of treated gout sits in, and it is genuinely confusing from the inside, because the treatment is doing something. Your number is lower than it was. You may even have been told it looks better.

The distance between those two panels is usually one or two more dose steps and a couple of blood tests. It is not a different drug.

The trial that measured it

In 2017 a New Zealand group ran the study this question deserved. They took 183 people with gout who were already on at least the allopurinol dose their kidney function called for, and who were still above target. Their average dose was 269 mg a day. Their average urate was 7.15 mg/dL.

Half continued at that dose. Half had their dose increased monthly — in 50 mg steps for those with reduced kidney function, 100 mg for everyone else — until their urate came under 6.0 mg/dL.

At twelve months:

• 69% of the dose-escalation group were under target
• 32% of those who stayed on their existing dose were

Same drug. Same people. The only variable was whether anyone kept turning the dial.

“But my kidneys”

This is where the stall usually originates, and it is worth addressing directly because it is the single most common reason a gout dose never moves.

Allopurinol dosing has historically been capped according to kidney function, out of concern about a rare but serious hypersensitivity reaction. That caution shaped a generation of prescribing, and it left a widespread impression that allopurinol is dangerous or off-limits in chronic kidney disease.

The 2020 guideline is unusually direct about this. It strongly recommends allopurinol as the preferred first-line agent for all patients — explicitly including those with stage 3 or worse chronic kidney disease. In the accompanying discussion it notes that patients with CKD “may still require dose titration above 300 mg/day to achieve the SU target.”

The same 2017 trial looked at exactly this. Among its participants, those with the worst kidney function (creatinine clearance under 30 ml/min) reached target at 64.3%, compared with 76.4% and 75.0% in the moderate and normal groups — no meaningful difference. They needed lower doses to get there (a mean of 250 mg/day, against 365 and 460 mg/day), and adverse events were similar across the groups.

Reduced kidney function changes what the right dose is. It does not change whether there is one.

There is one genuinely important exception to know about: the guideline conditionally recommends testing for the HLA–B*5801 gene variant before starting allopurinol in people of Southeast Asian descent (Han Chinese, Korean, Thai) and in African American patients, because that variant carries a substantially higher risk of the hypersensitivity reaction. It recommends against testing everyone else.

What to actually do with this

Nothing here is a reason to change your own dose, and you should not. Allopurinol titration is done alongside blood tests for a reason, and the low-and-slow approach exists precisely because going up too fast provokes flares.

What it is a reason to do is ask three questions at your next appointment:

1. What was my last serum urate, and when was it taken?
2. What number are we aiming for?
3. Has my dose changed since I started — and if I am not at target, what is the plan?

That third question is the one that does the work. It is not confrontational; it is the question the guideline assumes someone is asking. Often nobody is, because the appointment is short, the patient feels roughly the same as last time, and there is no obvious prompt to revisit a prescription that is not causing trouble.

Which is the practical case for keeping your own record. A dose history and a sequence of urate values, on one screen, turns a vague “still getting flares sometimes” into a specific and answerable question. That is the difference between a consultation that renews a prescription and one that adjusts it.

The Gout Journal app is built for exactly this: record each uric acid result, keep a log of the medication you are actually taking, and see the dose and the number on one timeline. Both go into a single report you can hand over at an appointment — so the answer to “has anything changed since I started?” is on the screen, rather than in either of your memories.

Gout Journal is written by someone who lives with gout, not by a clinician. This article is general information, not medical advice — never start, stop or change a medication without talking to your own doctor.